IGN 311

Drug Profile

IGN 311

Alternative Names: HuABL 364; Humanised anti-Lewis Y monoclonal antibody; IGN311; Monoclonal antibody SMART ABL 364; SMART ABL 364 antibody

Latest Information Update: 10 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Complement activation stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
  • 17 Nov 2005 IGN 311 has been licensed to Celltrion in certain Asian countries, including Japan
  • 21 Jul 2005 Clinical data from a media release have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top